Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
about
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addictionRon receptor tyrosine kinase signaling as a therapeutic targetRon knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapiesThe Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cellsPotential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancerRon-receptor tyrosine kinase in tumorigenesis and metastasisRon receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 productionMet-related receptor tyrosine kinase Ron in tumor growth and metastasis.Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice.Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell linesThe RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.RON is not a prognostic marker for resectable pancreatic cancer.Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.β-Catenin is required for Ron receptor-induced mammary tumorigenesisThe monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity.HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses.Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancerMyeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancerTherapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma.The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines.Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics.Emerging antibody combinations in oncology.Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.
P2860
Q26864275-0CF3B6D9-5D3E-42A5-A92F-9800B573C3B6Q27003295-26939D3F-E730-413D-9BB3-D423FE78A45BQ28534954-843F86B2-A07E-45A8-ABAE-0717512709FBQ33563635-323FE0F0-985F-4970-AC39-8B9BD0BF712BQ33592512-96E62F75-FBDD-4C72-B3D2-005CD8CFF81AQ33652455-6768F852-E22C-4B9B-92BC-11D2DC17D018Q33783151-E3F506DE-DD60-43DC-BFC7-F69F760923A9Q33850098-66A40E4D-05EE-4A1D-BB67-B805EB2913F5Q33850102-C2D3B606-FAFC-4CAC-8757-E619B4054500Q33916081-551A0969-290D-4115-A699-D22F458C7754Q34037017-768FE0BF-B8B1-4351-8DEB-8016F6236D0CQ34041328-4E1195FD-EA01-4795-A237-62E8C07DFB19Q34139704-58D89BDC-B80A-45AF-A46D-ED580DB29FD4Q34408923-BEDF0024-430B-4BEB-AA6B-D5D1B6784A62Q34518350-D2C430D7-AEF6-4E3C-B696-1BD7CFF19CDEQ35100064-BA53EE12-4832-4A5A-9617-E89261B3C044Q35124768-76EFE349-D8DE-40EF-9F64-00A43C42FAE7Q35144510-2CF88312-80DD-4E8B-8C02-BD4364C657D1Q35190869-7BFC5E8F-E49D-45F8-8C09-2288EC40C9ECQ35577352-605B8340-664A-4181-844B-8607B42A6845Q35986081-761DA056-B1B0-4385-9DB7-EF70B1DD2931Q36140785-FAE01BAD-B51E-455E-B8E4-1F5E007F526BQ36232073-1715D7FA-25FD-424C-9527-DE7130269FD5Q36377994-1984A4C4-6F65-43DF-A684-1C3A92CC3E97Q36492850-7A1D0540-1742-4044-ADF0-B125F75E2132Q36698670-31B6C84E-06D0-45FA-AACF-A28BBAE86D5FQ36814075-AAD873F5-0A8C-4F6C-BCE1-6C3C0C4E798FQ36824455-4D46F15B-B3FA-42FB-B894-54AE9DE5E533Q36958365-F824A4CB-2019-41C6-A6FE-5D6A8DBFA229Q36975164-6B0352DE-92D2-444D-941B-2F2C27204AF0Q37040636-FC7F099D-10CB-4B6A-A4A9-B3CDCAC264BEQ37066428-2BE0816F-A7C7-491A-9FFD-7898F90A14ADQ37275734-C619560E-2454-43B0-9C33-D721D3B7588EQ37564619-46A6DA4D-3BCA-4C9A-B92D-CBCEC0900839Q37893414-E76602C1-6D55-4DEB-B6F4-47F0D3E4F86EQ38922319-9907E301-EED2-4F29-94D3-BC4F5BD4495DQ39271429-22A3E452-C3E3-493A-B171-0CA0DC7CFC56Q39628474-A5E0715B-157E-444F-B944-C144EA313F76Q39676024-9FADF3D4-66C0-4F46-AE58-2489D81C541CQ39747567-DB6456AC-BFBB-45EB-88AA-A41C9B4F2395
P2860
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Therapeutic implications of a ...... (RON), a c-MET family member.
@ast
Therapeutic implications of a ...... (RON), a c-MET family member.
@en
type
label
Therapeutic implications of a ...... (RON), a c-MET family member.
@ast
Therapeutic implications of a ...... (RON), a c-MET family member.
@en
prefLabel
Therapeutic implications of a ...... (RON), a c-MET family member.
@ast
Therapeutic implications of a ...... (RON), a c-MET family member.
@en
P2093
P1433
P1476
Therapeutic implications of a ...... (RON), a c-MET family member.
@en
P2093
Dale L Ludwig
Daniel J Hicklin
Daniel S Pereira
Jennifer M O'Toole
Karen E Rabenau
Kerri Burns
Kimberly J Gottfredsen
Marie Prewett
Megan N Thobe
P304
P356
10.1158/0008-5472.CAN-06-0283
P407
P577
2006-09-01T00:00:00Z